Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer

Completed · Phase 3 · Has a placebo group

Conditions studied: Non-metastatic Prostate Cancer

In brief

The purpose of this trial is to study the effect - in terms of time to progression and overall survival - of 2 years of adjuvant bicalutamide 150mg monotherapy, versus placebo, in subjects with histologically or cytologically confirmed non-metastatic adenocarcinoma of the prostate gland.

Key facts

Study ID
NCT00657904
Run by
AstraZeneca
People needed
3618
Starts
1995-08-01
Expected to finish
2008-08-01
Last updated by the study team
2012-06-06

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.